Press coverage about Evolent Health (NYSE:EVH) has been trending somewhat positive on Thursday, according to Accern. The research group scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Evolent Health earned a news impact score of 0.14 on Accern’s scale. Accern also assigned news headlines about the technology company an impact score of 46.690079169587 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Evolent Health (EVH) opened at $13.85 on Thursday. The company has a current ratio of 3.34, a quick ratio of 3.34 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $1,105.91, a price-to-earnings ratio of -12.26 and a beta of 1.07. Evolent Health has a 1 year low of $10.30 and a 1 year high of $27.50.
Evolent Health (NYSE:EVH) last released its quarterly earnings results on Thursday, November 2nd. The technology company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.04. The company had revenue of $107.90 million during the quarter, compared to the consensus estimate of $104.49 million. Evolent Health had a negative return on equity of 5.05% and a negative net margin of 15.86%. Evolent Health’s revenue was up 79.2% compared to the same quarter last year. During the same quarter last year, the business posted ($0.26) earnings per share. sell-side analysts forecast that Evolent Health will post -0.57 EPS for the current fiscal year.
Several research firms recently weighed in on EVH. SunTrust Banks reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Evolent Health in a research note on Wednesday, September 20th. Robert W. Baird reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Evolent Health in a research note on Wednesday, November 1st. Zacks Investment Research downgraded Evolent Health from a “hold” rating to a “sell” rating in a research note on Monday, October 2nd. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Evolent Health in a research note on Sunday, December 3rd. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Evolent Health in a research note on Friday, October 6th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and thirteen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $28.00.
ILLEGAL ACTIVITY WARNING: “Evolent Health (NYSE:EVH) Given Daily News Sentiment Rating of 0.14” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/18/evolent-health-evh-given-daily-media-sentiment-rating-of-0-14.html.
Evolent Health Company Profile
Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.